These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17053276)

  • 1. European Medicines Agency policies for clinical trials leave women unprotected.
    Ruiz Cantero MT; Angeles Pardo M
    J Epidemiol Community Health; 2006 Nov; 60(11):911-3. PubMed ID: 17053276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation.
    Pignatti F; Gravanis I; Herold R; Vamvakas S; Jonsson B; Marty M
    Clin Cancer Res; 2011 Aug; 17(16):5220-5. PubMed ID: 21844037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of the Danish Medical Products Agency in clinical trials].
    Simonsen AC
    Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Medicines Agency: an unacceptable choice.
    Prescrire Int; 2011 Nov; 20(121):278. PubMed ID: 22066320
    [No Abstract]   [Full Text] [Related]  

  • 5. The European Medicines Agency: a public health European agency?
    Mahalatchimy A; Rial-Sebbag E; De Grove-Valdeyron N; Tournay V; Cambon-Thomsen A; Duguet AM; Taboulet F
    Med Law; 2012 Mar; 31(1):25-42. PubMed ID: 22908736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [European drug policy].
    Sauer F
    Bull Mem Acad R Med Belg; 1993; 148(5-6):207-12; discussion 212-6. PubMed ID: 8142930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMA consults public on plan to increase transparency of drug trial data.
    Cohen D
    BMJ; 2013 Jun; 346():f4124. PubMed ID: 23804186
    [No Abstract]   [Full Text] [Related]  

  • 8. Are women appropriately represented and assessed in clinical trials submitted for marketing authorization? A review of the database of the European Medicines Agency.
    Müllner M; Vamvakas S; Rietschel M; van Zwieten-Boot BJ
    Int J Clin Pharmacol Ther; 2007 Sep; 45(9):477-84. PubMed ID: 17907590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [EURO-Medicines: a European program for bringing into agreement public health policies on drugs].
    Calamo-Specchia F; Bucci R; Folino-Gallo P
    Ann Ig; 1998; 10(5-6):405-12. PubMed ID: 10052204
    [No Abstract]   [Full Text] [Related]  

  • 10. Transparency interrupted: the curtailment of the European Medicines Agency's Policy on access to documents.
    Doshi P
    JAMA Intern Med; 2013 Nov; 173(21):2009-11. PubMed ID: 23959623
    [No Abstract]   [Full Text] [Related]  

  • 11. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer.
    Doshi P; Jefferson T
    JAMA Intern Med; 2013 Mar; 173(5):380-2. PubMed ID: 23599918
    [No Abstract]   [Full Text] [Related]  

  • 12. Medicines to remain with European Commission health directorate.
    Watson R
    BMJ; 2014 Oct; 349():g6514. PubMed ID: 25355097
    [No Abstract]   [Full Text] [Related]  

  • 13. Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies.
    Lexchin J; O'Donovan O
    Soc Sci Med; 2010 Mar; 70(5):643-7. PubMed ID: 19782458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fostering EMA's transparency policy.
    Banzi R; Bertele' V; Demotes-Mainard J; Garattini S; Gluud C; Kubiak C; Ohmann C
    Eur J Intern Med; 2014 Oct; 25(8):681-4. PubMed ID: 25200801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The European Medicines Agency is still too close to industry.
    Garattini S
    BMJ; 2016 May; 353():i2412. PubMed ID: 27154140
    [No Abstract]   [Full Text] [Related]  

  • 16. [The inspection by the Danish Medical Products Agency of drug clinical trials].
    Jacobsen E; Stilbo I
    Ugeskr Laeger; 2003 Apr; 165(16):1656-8. PubMed ID: 12756822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US Public Health Agency involvement in youth-focused illicit drug policy, planning, and prevention at the local level, 1999-2003.
    McBride DC; Terry-McElrath YM; VanderWaal CJ; Chriqui JF; Myllyluoma J
    Am J Public Health; 2008 Feb; 98(2):270-7. PubMed ID: 18172140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European medicines agency: riddled with conflicts of interest.
    Prescrire Int; 2012 Nov; 21(132):278. PubMed ID: 23210268
    [No Abstract]   [Full Text] [Related]  

  • 19. Statistical resource needs to be increased in the European regulatory agencies.
    Keene ON; Hughes SH; Howitt N;
    Pharm Stat; 2011; 10(2):87-8. PubMed ID: 20143340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA).
    Ruperto N; Eichler I; Herold R; Vassal G; Giaquinto C; Hjorth L; Valls-i-Soler A; Peters C; Helms PJ; Saint Raymond A
    Arch Dis Child; 2012 Mar; 97(3):185-8. PubMed ID: 22123735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.